Under the agreement, Alfacell has granted Megapharm exclusive rights in the defined territory for the marketing, sales and distribution of Onconase. Alfacell will receive 50% of all sales in the territory.
In addition, Alfacell will manufacture and supply the product to Megapharm, while Megapharm will be responsible for all activities and costs related to regulatory filings and commercial activities in the territory.
Alfacell’s Onconase has recently completed an international confirmatory Phase IIIb clinical trial for unresectable malignant mesothelioma.
Kuslima Shogen, CEO of Alfacell, said: “Megapharm’s role as a leader in biotechnology marketing in Israel provides Alfacell with an ideal partner to maximize the potential of Onconase in this region. We look forward to a successful collaboration with Megapharm.”